Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $41.67, for a total value of $20,835.00. Following the transaction, the director now owns 78,833 shares in the company, valued at $3,284,971.11. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $42.46 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $35.93 and a twelve month high of $67.66. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. The company has a market cap of $2.07 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85. The company’s 50 day moving average is $43.48 and its 200 day moving average is $50.74.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The business had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. On average, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.41 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC lifted its stake in shares of Amphastar Pharmaceuticals by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock valued at $1,326,000 after purchasing an additional 169 shares during the period. Quadrant Capital Group LLC boosted its stake in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after acquiring an additional 223 shares in the last quarter. Bridge City Capital LLC increased its stake in shares of Amphastar Pharmaceuticals by 0.8% in the 1st quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock valued at $1,527,000 after purchasing an additional 275 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 1.3% during the third quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock worth $1,262,000 after purchasing an additional 358 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its position in shares of Amphastar Pharmaceuticals by 2.7% in the first quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock valued at $655,000 after buying an additional 399 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AMPH shares. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price target on the stock. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $66.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.